Fluorodeoxyglucose positron emission tomography in clinical oncology: the referrer's perspective

Nucl Med Commun. 2002 Nov;23(11):1041-6. doi: 10.1097/00006231-200211000-00002.

Abstract

From January 2000 to April 2002 a prospective audit based on a questionnaire was carried out concerning the attitudes and viewpoints of clinicians referring patients to fluorodeoxyglucose positron emission tomography (FDG PET) scanning. A standard and structured audit form was posted to each referring doctor with the formal clinical report issued by the nuclear medicine consultant. Three hundred and thirty evaluable forms were analysed, a return rate of approximately 22%, from a total of 1500 PET patients studied during this period. FDG PET scanning was deemed by the referring physician to have altered the staging of cancer patients in 39% of all cases. Twenty-five per cent of patients were upstaged with FDG PET and 14% of patients downstaged. Patient management was changed in 39% of cases whilst a change in treatment occurred in 10% of cases. The reported FDG PET study was judged as being helpful in over 75% of all cases. These data further support evidence of the increasing role of FDG studies in the investigation of patients with cancer.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Attitude of Health Personnel
  • Child
  • Decision Making
  • Disease Management
  • Female
  • Fluorodeoxyglucose F18*
  • Health Care Surveys*
  • Humans
  • Male
  • Medical Oncology / methods
  • Middle Aged
  • Neoplasm Staging / methods*
  • Neoplasm Staging / statistics & numerical data
  • Neoplasms / diagnosis*
  • Neoplasms / pathology
  • Neoplasms / therapy
  • Practice Patterns, Physicians'*
  • Prospective Studies
  • Radiopharmaceuticals
  • Referral and Consultation
  • Tomography, Emission-Computed / statistics & numerical data*
  • United Kingdom / epidemiology

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18